SBMFF News and Press, Sino Biopharmaceutical Ltd From 09/26/21

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survi...

The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...

Sino Biological completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock closed 68% higher at a market capitalization of $5.2 billion. Beijing InnoCare in-licensed greater China rights to a CD19 targeting mAb from Delaware-based Incyte in a $...

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome, a San Diego short-read company, for up to $800 million. Shanghai's Zai Lab and Schrödinger of New York formed a global collaboration to develop a novel oncology pr...

Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic HONG KONG, July 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiar...

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion HONG KONG, May 24, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Gr...

Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity HONG KONG, Mar 23, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovati...

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reported Sino Biopharma of Hong Kong will invest $515 million in a Sinovac subsidiary to dou...

Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V. Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac....

Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China HONG KONG, Dec 7, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., L...